{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Men&page=44",
    "query": {
      "condition": "Men",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 1690,
    "total_pages": 169,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Men&page=45&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Men&page=43&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T05:09:35.499Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02228265",
      "title": "Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Castration Levels of Testosterone",
        "Castration-Resistant Prostate Carcinoma",
        "Prostate Adenocarcinoma",
        "PSA Progression",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 41,
      "start_date": "2013-03-12",
      "completion_date": "2020-02-27",
      "has_results": false,
      "last_update_posted_date": "2020-09-28",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • San Francisco, California • Portland, Oregon",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02228265"
    },
    {
      "nct_id": "NCT04558567",
      "title": "Vogelxo(R) ABPM Study in Hypogandal Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypogonadism, Male"
      ],
      "interventions": [
        {
          "name": "Vogelxo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Upsher-Smith Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 122,
      "start_date": "2020-08-28",
      "completion_date": "2024-01-11",
      "has_results": false,
      "last_update_posted_date": "2024-10-18",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Garden City",
          "state": "New York"
        },
        {
          "city": "North Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04558567"
    },
    {
      "nct_id": "NCT05075967",
      "title": "Getting to Zero Among HHI MSM in the American South",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Health Access Coalitions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Social Media",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Peer Support",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Promoting Human Autonomy Support & Empathy (PHASE)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "HIV Prevention Trials Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "15 Years and older · Male only"
      },
      "enrollment_count": 2700,
      "start_date": "2025-12-10",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05075967"
    },
    {
      "nct_id": "NCT00146107",
      "title": "Weight Loss and Exercise in Obese, Physically Limited, Older Women and Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Diet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Exercise",
          "type": "OTHER"
        },
        {
          "name": "Weight Loss and Exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 107,
      "start_date": "2005-01",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2013-04-23",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146107"
    },
    {
      "nct_id": "NCT02200614",
      "title": "Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer Non-Metastatic",
        "Castration-Resistant"
      ],
      "interventions": [
        {
          "name": "Darolutamide (Nubeqa, BAY1841788)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1509,
      "start_date": "2014-09-12",
      "completion_date": "2021-06-14",
      "has_results": true,
      "last_update_posted_date": "2022-06-28",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 55,
      "location_summary": "Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 48 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02200614"
    },
    {
      "nct_id": "NCT00450619",
      "title": "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Samarium Sm 153 lexidronam pentasodium",
          "type": "RADIATION"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant vaccinia-TRICOM vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant fowlpox-TRICOM vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 44,
      "start_date": "2007-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-04",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Bethesda, Maryland • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00450619"
    },
    {
      "nct_id": "NCT04473651",
      "title": "Safety and Tolerability of Lu AG06479 in Healthy Young Men",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lu AG06479",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2020-07-09",
      "completion_date": "2021-11-10",
      "has_results": false,
      "last_update_posted_date": "2021-12-14",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04473651"
    },
    {
      "nct_id": "NCT00397839",
      "title": "The Effect Of Oral Ibandronate In Male Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Male Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Ibandronate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "30 Years and older · Male only"
      },
      "enrollment_count": 135,
      "start_date": "2007-01",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2009-12-21",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00397839"
    },
    {
      "nct_id": "NCT01682941",
      "title": "Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Arm I Soy Bread",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Arm II Soy-Almond Bread",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 32,
      "start_date": "2009-10",
      "completion_date": "2023-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-11-22",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682941"
    },
    {
      "nct_id": "NCT04592237",
      "title": "Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aggressive Variant Prostate Carcinoma",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Metastatic Prostate Neuroendocrine Carcinoma",
        "Metastatic Prostate Small Cell Carcinoma",
        "Stage IV Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetrelimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2020-12-29",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-31T05:09:35.499Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04592237"
    }
  ]
}